Compare TGHL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGHL | BIVI |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.5M |
| IPO Year | N/A | 2013 |
| Metric | TGHL | BIVI |
|---|---|---|
| Price | $0.40 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.5K | ★ 53.6K |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.82 |
| 52 Week High | $3.80 | $9.09 |
| Indicator | TGHL | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 63.09 |
| Support Level | $0.33 | $1.52 |
| Resistance Level | $0.38 | $1.68 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 60.09 | 96.23 |
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.